Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2CLIMB-02: Tucatinib plus T-DM1 vs placebo plus T-DM1 in unresectable locally advanced or metastatic HER2-positive breast cancer
jRCT2051200068Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of tucatinib in breast cancer (3 arms), sponsored by Pfizer. Primary endpoints: Safety and tolerability in Japan-specific safety run-in and Progression-free survival (PFS) by investigator per RECIST v1.1. Started Oct 2020; status: active, not recruiting.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2051200068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200068.